Archives
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
Single cilta-cel infusion results in lower risk of disease progression or death compared with standard care
ASCO: Drug Combo Ups Progression-Free Survival for Metastatic Prostate Cancer
Improvement in radiographic progression-free survival seen for talazoparib plus enzalutamide as first-line treatment
ASCO: Extended Lymph Node Removal Not Beneficial for Bladder Cancer
No benefit in terms of disease-free or overall survival seen for those with muscle-invasive bladder cancer undergoing radical cystectomy
ASCO: Germline Testing Underused in Cancer Patients
Rates of testing lower among Asian, Black, and Hispanic patients versus White patients
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention
Early Treatment Can Be Initiated for A-Fib Patients With Stroke
Incidence of primary end point ranged from reduction of about 2.8 percent to increase of about 0.5 percent
ASCO: Microbiome Varies for Early-Onset, Late-Onset Colorectal Cancer
Cladosporium sp. was more commonly found in early-onset CRC, while Pseudomonas luteola, Ralstonia sp., Moraxella osloensis occurred more often in late-onset CRC
ASCO: Phone-Based Coaching Helps Breast Cancer Patients Lose Weight
Authors say next step in research is to see if weight loss impacts cancer recurrence
Hemodynamic Monitoring Beneficial for Chronic Heart Failure
Improvement seen in Kansas City Cardiomyopathy Questionnaire with CardioMEMS-HF system versus standard care
